NAU publications by CHER
Faculty & staff publications
NAU faculty and staff have the opportunity to publish their findings and knowledge as authors. CHER has many researchers that have been cited multiple times in major publications for their great work. The Center for Health Equity Research has accumulated all faculty publications into one, easy to navigate database.
Please type in a key word or author LAST name to search
Wohl, David A; Panter, A T; Kirby, Christine; Magnus, Brokke E; Hudgens, Michael G; Allmon, Andrew G; Mollan, Katie R Estimating HIV medication adherence and persistence: Two instruments for clinical and research use Journal Article AIDS and Behavior, 22 (3), pp. 948-960, 2018. @article{Wohl2018, title = {Estimating HIV medication adherence and persistence: Two instruments for clinical and research use}, author = {David A Wohl and A T Panter and Christine Kirby and Brokke E Magnus and Michael G Hudgens and Andrew G Allmon and Katie R Mollan}, url = {https://link.springer.com/article/10.1007/s10461-017-1772-z}, doi = {10.1007/s10461-017-1772-z}, year = {2018}, date = {2018-03-01}, journal = {AIDS and Behavior}, volume = {22}, number = {3}, pages = {948-960}, abstract = {Antiretroviral therapy (ART) requires lifelong daily oral therapy. While patient characteristics associated with suboptimal ART adherence and persistence have been described in cohorts of HIV-infected persons, these factors are poor predictors of individual medication taking behaviors. We aimed to create and test instruments for the estimation of future ART adherence and persistence for clinical and research applications. Following formative work, a battery of 148 items broadly related to HIV infection and treatment was developed and administered to 181 HIV-infected patients. ART adherence and persistence were assessed using electronic monitoring for 3 months. Perceived confidence in medication taking and self-reported barriers to adherence were strongest in predicting non-adherence over time. Barriers to adherence (e.g., affordability, scheduling) were the strongest predictors of non-adherence, as well as 3- and 7-day non-persistence. A ten-item battery for prediction of these outcomes (www.med.unc.edu/ncaidstraining/adherence/for-providers) and a 30-item battery reflective of underlying psychological constructs can help identify and study individuals at risk for suboptimal ART adherence and persistence.}, keywords = {}, pubstate = {published}, tppubtype = {article} } Antiretroviral therapy (ART) requires lifelong daily oral therapy. While patient characteristics associated with suboptimal ART adherence and persistence have been described in cohorts of HIV-infected persons, these factors are poor predictors of individual medication taking behaviors. We aimed to create and test instruments for the estimation of future ART adherence and persistence for clinical and research applications. Following formative work, a battery of 148 items broadly related to HIV infection and treatment was developed and administered to 181 HIV-infected patients. ART adherence and persistence were assessed using electronic monitoring for 3 months. Perceived confidence in medication taking and self-reported barriers to adherence were strongest in predicting non-adherence over time. Barriers to adherence (e.g., affordability, scheduling) were the strongest predictors of non-adherence, as well as 3- and 7-day non-persistence. A ten-item battery for prediction of these outcomes (www.med.unc.edu/ncaidstraining/adherence/for-providers) and a 30-item battery reflective of underlying psychological constructs can help identify and study individuals at risk for suboptimal ART adherence and persistence. |
Pohl, David A; Kuwahara, Rita K; Javadi, Kamran; Kirby, Christine; Rosen, David L; Napravnik, Sonia; Farel, Claire Financial barriers and lapses in treatment and care of HIV-infected adults in a southern state in the United States Journal Article AIDS Patient Care and STDs, 31 (11), pp. 463-469, 2017. @article{Pohl2017, title = {Financial barriers and lapses in treatment and care of HIV-infected adults in a southern state in the United States}, author = {David A Pohl and Rita K Kuwahara and Kamran Javadi and Christine Kirby and David L Rosen and Sonia Napravnik and Claire Farel}, url = {https://www.liebertpub.com/doi/abs/10.1089/apc.2017.0125}, year = {2017}, date = {2017-11-01}, journal = {AIDS Patient Care and STDs}, volume = {31}, number = {11}, pages = {463-469}, abstract = {Antiretroviral (ARV) adherence has largely been considered from the perspective of an individual's behavior with less attention given to potential structural causes for lapses in treatment, such as the cost of medications and care. HIV medication expense is typically covered by third party payers. However, private insurance premiums and deductibles may rise, or policies terminated such as with a change in employment. Likewise, a patient's eligibility for publicly funded coverage like state AIDS Drug Assistance Programs (ADAP) or Medicaid can also be lost. We conducted a one-time survey of a sample of 300 patients receiving HIV care at a single large academic center in the south of United States to examine lapses in HIV therapy due to financial reasons. We found that during the prior year, financial issues including medication cost or coverage led to a lapse in ARVs in 10% (n = 31) of participants. However, of …}, keywords = {}, pubstate = {published}, tppubtype = {article} } Antiretroviral (ARV) adherence has largely been considered from the perspective of an individual's behavior with less attention given to potential structural causes for lapses in treatment, such as the cost of medications and care. HIV medication expense is typically covered by third party payers. However, private insurance premiums and deductibles may rise, or policies terminated such as with a change in employment. Likewise, a patient's eligibility for publicly funded coverage like state AIDS Drug Assistance Programs (ADAP) or Medicaid can also be lost. We conducted a one-time survey of a sample of 300 patients receiving HIV care at a single large academic center in the south of United States to examine lapses in HIV therapy due to financial reasons. We found that during the prior year, financial issues including medication cost or coverage led to a lapse in ARVs in 10% (n = 31) of participants. However, of … |
2018 |
Wohl, David A; Panter, A T; Kirby, Christine; Magnus, Brokke E; Hudgens, Michael G; Allmon, Andrew G; Mollan, Katie R Estimating HIV medication adherence and persistence: Two instruments for clinical and research use Journal Article AIDS and Behavior, 22 (3), pp. 948-960, 2018. @article{Wohl2018, title = {Estimating HIV medication adherence and persistence: Two instruments for clinical and research use}, author = {David A Wohl and A T Panter and Christine Kirby and Brokke E Magnus and Michael G Hudgens and Andrew G Allmon and Katie R Mollan}, url = {https://link.springer.com/article/10.1007/s10461-017-1772-z}, doi = {10.1007/s10461-017-1772-z}, year = {2018}, date = {2018-03-01}, journal = {AIDS and Behavior}, volume = {22}, number = {3}, pages = {948-960}, abstract = {Antiretroviral therapy (ART) requires lifelong daily oral therapy. While patient characteristics associated with suboptimal ART adherence and persistence have been described in cohorts of HIV-infected persons, these factors are poor predictors of individual medication taking behaviors. We aimed to create and test instruments for the estimation of future ART adherence and persistence for clinical and research applications. Following formative work, a battery of 148 items broadly related to HIV infection and treatment was developed and administered to 181 HIV-infected patients. ART adherence and persistence were assessed using electronic monitoring for 3 months. Perceived confidence in medication taking and self-reported barriers to adherence were strongest in predicting non-adherence over time. Barriers to adherence (e.g., affordability, scheduling) were the strongest predictors of non-adherence, as well as 3- and 7-day non-persistence. A ten-item battery for prediction of these outcomes (www.med.unc.edu/ncaidstraining/adherence/for-providers) and a 30-item battery reflective of underlying psychological constructs can help identify and study individuals at risk for suboptimal ART adherence and persistence.}, keywords = {}, pubstate = {published}, tppubtype = {article} } Antiretroviral therapy (ART) requires lifelong daily oral therapy. While patient characteristics associated with suboptimal ART adherence and persistence have been described in cohorts of HIV-infected persons, these factors are poor predictors of individual medication taking behaviors. We aimed to create and test instruments for the estimation of future ART adherence and persistence for clinical and research applications. Following formative work, a battery of 148 items broadly related to HIV infection and treatment was developed and administered to 181 HIV-infected patients. ART adherence and persistence were assessed using electronic monitoring for 3 months. Perceived confidence in medication taking and self-reported barriers to adherence were strongest in predicting non-adherence over time. Barriers to adherence (e.g., affordability, scheduling) were the strongest predictors of non-adherence, as well as 3- and 7-day non-persistence. A ten-item battery for prediction of these outcomes (www.med.unc.edu/ncaidstraining/adherence/for-providers) and a 30-item battery reflective of underlying psychological constructs can help identify and study individuals at risk for suboptimal ART adherence and persistence. |
2017 |
Pohl, David A; Kuwahara, Rita K; Javadi, Kamran; Kirby, Christine; Rosen, David L; Napravnik, Sonia; Farel, Claire Financial barriers and lapses in treatment and care of HIV-infected adults in a southern state in the United States Journal Article AIDS Patient Care and STDs, 31 (11), pp. 463-469, 2017. @article{Pohl2017, title = {Financial barriers and lapses in treatment and care of HIV-infected adults in a southern state in the United States}, author = {David A Pohl and Rita K Kuwahara and Kamran Javadi and Christine Kirby and David L Rosen and Sonia Napravnik and Claire Farel}, url = {https://www.liebertpub.com/doi/abs/10.1089/apc.2017.0125}, year = {2017}, date = {2017-11-01}, journal = {AIDS Patient Care and STDs}, volume = {31}, number = {11}, pages = {463-469}, abstract = {Antiretroviral (ARV) adherence has largely been considered from the perspective of an individual's behavior with less attention given to potential structural causes for lapses in treatment, such as the cost of medications and care. HIV medication expense is typically covered by third party payers. However, private insurance premiums and deductibles may rise, or policies terminated such as with a change in employment. Likewise, a patient's eligibility for publicly funded coverage like state AIDS Drug Assistance Programs (ADAP) or Medicaid can also be lost. We conducted a one-time survey of a sample of 300 patients receiving HIV care at a single large academic center in the south of United States to examine lapses in HIV therapy due to financial reasons. We found that during the prior year, financial issues including medication cost or coverage led to a lapse in ARVs in 10% (n = 31) of participants. However, of …}, keywords = {}, pubstate = {published}, tppubtype = {article} } Antiretroviral (ARV) adherence has largely been considered from the perspective of an individual's behavior with less attention given to potential structural causes for lapses in treatment, such as the cost of medications and care. HIV medication expense is typically covered by third party payers. However, private insurance premiums and deductibles may rise, or policies terminated such as with a change in employment. Likewise, a patient's eligibility for publicly funded coverage like state AIDS Drug Assistance Programs (ADAP) or Medicaid can also be lost. We conducted a one-time survey of a sample of 300 patients receiving HIV care at a single large academic center in the south of United States to examine lapses in HIV therapy due to financial reasons. We found that during the prior year, financial issues including medication cost or coverage led to a lapse in ARVs in 10% (n = 31) of participants. However, of … |